An accompanying article discusses the uncertainties as to whether recent therapeutic approaches (glucagon-like peptide 1 agonists, dipeptidyl peptidase 4 inhibitors, and sodium-glucose cotransporter inhibitors) alter cardiovascular and renal risk. The authors discuss the various studies of these agents which have identified their impact on cardiovascular and renal risk, including the results of this current study: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial of liraglutide.